Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 29, 2015

KRAIG BIOCRAFT LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Wyoming		83-0459707
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

120 N. Washington Square, Suite 805, Lansing, Michigan		48933
(Address of principal executive offices)		(Zip Code)

(517) 336-0807

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Copies to:

Hunter Taubman Weiss LLP

130 W. 42nd Street

Floor 10

New York, NY 10036

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 7 - Regulation FD

Item 7.01. Regulation FD Disclosure

Section 8 – Other Events

Item 8.01 – Other Events

On April 23, 2015, we retained Hunter Taubman Weiss LLP (“HTW”) as our new outside securities counsel. Initially, HTW will assist us with responding to the Securities and Exchange Commission’s comments to our Registration Statement on Form S-1 and the related amendment and then will provide us with ongoing legal support related to corporate and securities compliance, including assistance with our periodic reports on Form 10-K, 10-Q and ordinary current reports on Form 8-K as required by the Securities Exchange Act of 1934, as amended, preparation of routine annual reports, and similar items.

A press release relating to the matters disclosed herein shall be filed imminently. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Information contained herein, including Exhibit 99.1, shall not be deemed filed for the purposes of the Securities Exchange Act of 1934, as amended, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit		Description
99.1		Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	Kraig Biocraft Laboratories, Inc.

Date: April 29, 2015	By:	/s/ Kim Thompson
		Kim Thompson,
		Chief Executive Officer

Exhibit 99.1

KRAIG BIOCRAFT LABORATORIES APPOINTS Hunter Taubman Weiss LLP AS SECURITIES COUNSEL

LANSING, Mich., –April 30th, 2015 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that it has retained the New York law firm of Hunter Taubman Weiss LLP as legal counsel for all securities related matters.

“We are happy to announce that Hunter Taubman Weiss LLP will be representing the Company for SEC filings, compliance and general securities related matters” said Company founder and CEO Kim Thompson. “We are very pleased to be in a position to make this appointment as we strengthen our management support team. Hunter Taubman Weiss LLP has a proven track record for supporting a growing business such as ours. We believe that the addition of Hunter Taubman Weiss LLP to the Kraig labs team will help improve our communications with both regulators and the investment community. This move is a planned component of our future growth plans. Their reputation for delivering outstanding client support in the areas of securities law and mergers & acquisitions was a key element of our decision. We look forward to working with them as we institute our plans to expand Kraig Labs operations.”

The law firm of Hunter Taubman Weiss LLP (HTW) possess a broad base of knowledge and extensive experience in the areas of securities and mergers & acquisitions. As a result of the global nature of HTW’s practice, they have attorneys fluent in English, Spanish, Portuguese, Mandarin and Cantonese. They serve a wide range of public companies, focused on growth, trading on the NASDAQ, and NYSE. HTW will serve as the primary interface for Kraig Labs SEC communications and filings, with the goal of improving both the speed and effectiveness of all future filings.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass.

These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Mar 2024 to Apr 2024